JP2007509063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509063A5 JP2007509063A5 JP2006535420A JP2006535420A JP2007509063A5 JP 2007509063 A5 JP2007509063 A5 JP 2007509063A5 JP 2006535420 A JP2006535420 A JP 2006535420A JP 2006535420 A JP2006535420 A JP 2006535420A JP 2007509063 A5 JP2007509063 A5 JP 2007509063A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- population
- vaccine
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 229940030156 cell vaccine Drugs 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 2
- 102000047918 Myelin Basic Human genes 0.000 claims 2
- 101710107068 Myelin basic protein Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003226 mitogen Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 108010062580 Concanavalin A Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000055324 Myelin Proteolipid Human genes 0.000 claims 1
- 108700021862 Myelin Proteolipid Proteins 0.000 claims 1
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 claims 1
- 102000016202 Proteolipids Human genes 0.000 claims 1
- 108010010974 Proteolipids Proteins 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
Claims (11)
- 多発性硬化症の処置のための自己Ｔ細胞ワクチンを作製する方法であって、以下：
（ａ）該ワクチンで処置されるべき患者に由来するＴ細胞を含む末梢血単核細胞の集団を提供する工程；
（ｂ）ＣＤ４＋Ｔ細胞集団を減らす工程；
（ｃ）ＭＳ関連抗原および必要に応じて抗原提示細胞を添加する工程；および
（ｄ）工程（ｃ）を１回以上反復する工程；
を包含し、該ＣＤ４ ＋ Ｔ細胞集団を減らす工程は、該末梢血単核細胞からＣＤ４ ＋ 細胞を除去することによる、方法。 - 前記ＭＳ関連抗原が、ミエリン塩基性タンパク質、プロテオリピドタンパク質、ミエリン稀突起神経膠細胞糖タンパク質およびこれらの組合せからなる群より選択される、請求項１に記載の方法。
- 前記ＭＳ関連抗原が、配列番号１〜４のいずれか１つに記載の配列を含む、請求項１に記載の方法。
- 工程（ｃ）が、ＩＬ−２を添加する工程をさらに包含する、請求項１に記載の方法。
- 工程（ｃ）が、マイトジェンを添加する工程をさらに包含する、請求項１に記載の方法。
- 前記マイトジェンが、フィトヘマグルチニン、コンカナバリンＡ、アメリカヤマゴボウマイトジェン、および抗ＣＤ３モノクローナル抗体からなる群より選択される、請求項５に記載の方法。
- 請求項１〜６のいずれか１つに記載の方法により作製された、自己Ｔ細胞ワクチン。
- 多発性硬化症を処置するための、請求項７に記載の自己Ｔ細胞ワクチン。
- ＭＳ関連抗原に反応性のＣＤ８ ＋ Ｔ細胞の富化集団を含む自己Ｔ細胞ワクチンであって、ＣＤ４＋Ｔ細胞集団が減らされている、ワクチン。
- ＭＳ関連抗原に反応性のＣＤ８ ＋ Ｔ細胞の富化集団を含む自己Ｔ細胞ワクチンであって、該ＭＳ関連抗原が、ミエリン塩基性タンパク質、プロテオリピドタンパク質およびミエリン稀突起神経膠細胞糖タンパク質からなる群より選択される、ワクチン。
- ＭＳ関連抗原に反応性のＣＤ８ ＋ Ｔ細胞の富化集団を含む自己Ｔ細胞ワクチンであって、該ＭＳ関連抗原が、配列番号１〜４のいずれか１つに記載される配列を含む、ワクチン。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51221203P | 2003-10-17 | 2003-10-17 | |
| PCT/US2004/034448 WO2005037309A1 (en) | 2003-10-17 | 2004-10-18 | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509063A JP2007509063A (ja) | 2007-04-12 |
| JP2007509063A5 true JP2007509063A5 (ja) | 2007-11-29 |
Family
ID=34465326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535420A Pending JP2007509063A (ja) | 2003-10-17 | 2004-10-18 | Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20080107664A1 (ja) |
| EP (1) | EP1677821B1 (ja) |
| JP (1) | JP2007509063A (ja) |
| CN (1) | CN1893971A (ja) |
| AU (1) | AU2004281817B2 (ja) |
| BR (1) | BRPI0415519A (ja) |
| CA (1) | CA2542668C (ja) |
| IL (1) | IL174935A (ja) |
| NZ (1) | NZ546552A (ja) |
| WO (1) | WO2005037309A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080107664A1 (en) * | 2003-10-17 | 2008-05-08 | Zang Ying C Q | Method For Increasing Cd8+ Cytotoxic T Cell Responses And For Treating Multiple Sclerosis |
| PT2016414E (pt) * | 2006-05-05 | 2015-11-24 | Opexa Therapeutics | Vacina de células t |
| EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| WO2011060329A1 (en) * | 2009-11-14 | 2011-05-19 | Kuang-Yuh Chyu | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| RU2435556C1 (ru) * | 2010-04-23 | 2011-12-10 | Владимир Васильевич Лантух | Способ лечения дистрофических заболеваний заднего полюса глаза |
| WO2013063713A1 (zh) * | 2011-10-31 | 2013-05-10 | 鑫品生医科技股份有限公司 | 诱发产生综合免疫细胞的方法 |
| CN105085616A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种氨基酸序列及其应用 |
| CN105085615A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种多肽序列及其应用 |
| RU2769474C2 (ru) * | 2017-01-20 | 2022-04-01 | Атара Байотерапьютикс, Инк. | Способы лечения рассеянного склероза с использованием аутологичных т-клеток |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2133749A1 (en) | 1992-04-09 | 1993-10-28 | Howard L. Weiner | Suppression of t-cell proliferation using peptide fragments of myelin basic protein |
| US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| JP2002513008A (ja) | 1998-04-29 | 2002-05-08 | ジョージタウン ユニヴァーシティー | Ｈｌａ−作動薬及び拮抗薬としてのｈｌａ結合性化合物の同定及び使用方法 |
| US7811816B2 (en) * | 2001-05-15 | 2010-10-12 | Ortho-Mcneil Pharmaeutical, Inc. | Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| US20080107664A1 (en) * | 2003-10-17 | 2008-05-08 | Zang Ying C Q | Method For Increasing Cd8+ Cytotoxic T Cell Responses And For Treating Multiple Sclerosis |
-
2004
- 2004-10-18 US US10/575,831 patent/US20080107664A1/en not_active Abandoned
- 2004-10-18 WO PCT/US2004/034448 patent/WO2005037309A1/en not_active Ceased
- 2004-10-18 NZ NZ546552A patent/NZ546552A/en not_active IP Right Cessation
- 2004-10-18 AU AU2004281817A patent/AU2004281817B2/en not_active Ceased
- 2004-10-18 CA CA2542668A patent/CA2542668C/en not_active Expired - Fee Related
- 2004-10-18 EP EP04795590A patent/EP1677821B1/en not_active Expired - Lifetime
- 2004-10-18 CN CNA2004800372329A patent/CN1893971A/zh active Pending
- 2004-10-18 JP JP2006535420A patent/JP2007509063A/ja active Pending
- 2004-10-18 BR BRPI0415519-0A patent/BRPI0415519A/pt not_active Application Discontinuation
-
2006
- 2006-04-11 IL IL174935A patent/IL174935A/en not_active IP Right Cessation
-
2009
- 2009-12-03 US US12/630,228 patent/US20100183546A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blair et al. | Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells | |
| Becher et al. | TH17 cytokines in autoimmune neuro-inflammation | |
| Aubert et al. | Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection | |
| RU2015138483A (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
| JP2007509063A5 (ja) | ||
| PL351893A1 (en) | Vaccines | |
| Nian et al. | Activated γδ T cells promote the activation of uveitogenic T cells and exacerbate EAU development | |
| DK0633929T3 (da) | Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener | |
| RU2005137167A (ru) | Композиции и способы для wt1 специфической иммунотерапии | |
| CN107254439A (zh) | 增强自然杀伤细胞增殖和活性的方法 | |
| DK1326961T3 (da) | Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner | |
| TW200506061A (en) | Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines | |
| EP2301356A3 (en) | Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors | |
| Goldmann et al. | Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance | |
| ATE389712T1 (de) | Krebs immuntherapie mit semi-allogenen zellen | |
| JP2006519228A5 (ja) | 抗原に対し霊長類を免疫寛容化する抗体の使用法 | |
| Cheever et al. | Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro | |
| Rahbar et al. | Agent-based modeling of tumor and immune system interactions in combinational therapy with low-dose 5-fluorouracil and dendritic cell vaccine in melanoma B16F10 | |
| JP2022023136A5 (ja) | ||
| JP2005034154A5 (ja) | ||
| JP2020535832A5 (ja) | ||
| JP2019508056A5 (ja) | ||
| MY127452A (en) | Vaccines. | |
| NO983917D0 (no) | Anvendelse av IL-7 for behandling av autoimmune sykdommer og særlig insulinavhengig diabetes mellitus | |
| WO2002043651A8 (en) | Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |